SKYE - Skye Bioscience rises 10% on IRB approval for phase 2 trial for ophthalmic emulsion
- Skye Bioscience ( OTCQB:SKYE ) is trading 10% higher after its Phase 2 trial protocol had received approval from a central institutional review board for SBI-100 Ophthalmic Emulsion in patients with primary open angle glaucoma or ocular hypertension.
- An IRB, operates under FDA regulations, assures that appropriate steps are taken to protect the rights and welfare of human subjects participating in biomedical research.
- IRBs review research protocols and related materials and have authority to approve, require modifications in, or disapprove research.
- The first cohort of patients in first-in-human Phase 1 trial in Australia was dosed in December.
For further details see:
Skye Bioscience rises 10% on IRB approval for phase 2 trial for ophthalmic emulsion